Get Cash Back and $0 Commissions
+ The Power of TradeStation

Allermi Secures $3.5M in Seed Funding to Meet Growing Demand for Customized Approach to Allergy Symptoms

Business Wire 16-Mar-2023 11:00 AM

World's First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion

Allermi, a direct-to-consumer telehealth service providing a customized approach to allergy relief, today announced a $3.5M seed round to continue its mission to deliver a personalized solution to allergy care. The round was led by Nelstone Ventures, who twice funded Apostrophe - a direct-to-consumer telehealth service providing customized skincare solutions - and helped lead their nine figure sale to Hims & Hers (NYSE:HIMS). In addition to Nelstone Ventures, FourSight Capital Partners also participated in the round.

This press release features multimedia. View the full release here:

World's First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion. (Graphic: Business Wire)

World's First Customized Multi-Ingredient Nasal Spray Secures Funding to Support Massive Expansion. (Graphic: Business Wire)

Allermi was co-founded by Dr. Robert Bocian, an allergist for more than 30 years, associate professor of allergy-immunology at Stanford and inventor of Bocian's Potions, the world's first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients' specific symptoms.

Allermi launched in California last July with a $1.25M pre-seed round led by Lucas Venture Group and has been growing rapidly over 30% month-over-month. Today, Allermi is available across 28 states nationwide. The seed funding will be used to continue national expansion; build and scale business, marketing and product operations; and enlarge marketing channels to meet the growing demand.

"There are approximately 110 million Americans that suffer from nasal congestion and rhinitis. With a custom combination of the right medications at the right dosage, millions of rhinitis sufferers can now achieve far superior relief compared to one-size-fits-all options at the drugstore," said Co-Founder and CEO Shani Bocian. "This recent funding will allow us to continue innovating our customized solution and make it accessible to allergy sufferers nationwide."

Despite an abundance of over-the-counter treatments and billions of dollars spent per year, only 30% of allergy sufferers are satisfied with available allergy medications. Allermi provides a personalized solution with over 90% of patients reporting superior relief.

"We first met the Allermi team nearly a year ago and were intrigued by their approach to improving patient care for rhinitis and allergy sufferers through their customized solutions and telemedicine offering," said Rich Nelson, Founder & Managing Director of Nelstone Ventures. "Since then, we have been very impressed with all that CEO Shani Bocian and the rest of the team have accomplished and are very excited to partner with them as they enter their next phase of growth and expansion."

After completing an online questionnaire that is then evaluated by an Allermi physician, patients are prescribed a customized nasal spray containing up to four active medication ingredients, combined and dosed for each patient's unique symptoms and severity.

Delivered by mail on a monthly or on-demand basis, each Allermi patient receives a personalized treatment plan, along with access to a dedicated care team which patients can contact for ongoing support.

Allermi is currently available to residents 18 or older in 28 states including: Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Iowa, Kentucky, Massachusetts, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Vermont and Washington.

For a limited time, Allermi is offering a free one-month trial to new patients. To learn more and sign up, please visit

Image for Press Release 1661352